MTOR and breast carcinoma: So, acquired resistance to hormone therapy and overexpression of EGFR/HER2 and activation of EGFR/HER2/MAPK pathway may counterbalance the mTOR activation by PI3K/AKT providing breast cancer cells with potent oncogenic signaling and high levels of cytoprotective autophagy.